A Multi-center, Double-blind, Placebo-controlled Phase 4 Study in Patients With Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Daily Life Physical Activity and Patient's Self-reported Symptoms and Their Impacts
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 17 Oct 2019
Price : $35 *
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms TRACE
- Sponsors Actelion Pharmaceuticals
- 13 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 09 Jul 2019 Planned End Date changed from 28 Jun 2019 to 28 Jun 2020.
- 09 Jul 2019 Planned primary completion date changed from 28 Jun 2019 to 28 Jun 2020.